Novel therapeutic approach against Epstein-Barr virus-associated tumors — ScienceDaily

A research team at LKS Faculty of Medicine, The University of Hong Kong (HKUMed) discovered that exosomes derived from V?2-T cells (Vδ2-T-Exos) can effectively control Epstein-Barr virus-associated tumours and induce T-cell anti-tumour immunity. The novel findings of Vδ2-T-Exos provide insights into new therapeutic approach for Epstein-Barr virus (EBV)-associated tumours. The ground-breaking findings have been published in the leading academic journal, Science Translational Medicine.

EBV infects about 95% of the human population and causes more than 200,000 cases of cancer each year and that around 2% of all cancer deaths are due to EBV-attributable malignancies. EBV-associated tumours include Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, gastric tumour and post-transplant lymphoproliferative disease, etc. Current treatment options for EBV-associated tumours are limited with considerably unwanted off-target toxicities and incomplete effectiveness for relapsed or refractory disease. V?2-T cells are innate-like T cells with anti-tumour potentials against EBV-associated tumours. Unfortunately, its clinical translation is limited

Read More
Read More

AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and COVID-19, announced today the publication of the peer-reviewed manuscript, “Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,” in the journal Investigative Ophthalmology & Visual Science. The study, led by researchers at AIVITA Biomedical and the Sue & Bill Gross Stem Cell Research Center of the University of California, Irvine, used 3D-retina organoids generated from human stem cells developed by AIVITA to provide insight into the potential use of transplanted retina organoids as a therapeutic option for blinding diseases.

In the study, transplanted retina organoid sheets were examined to determine if human stem cell-derived photoreceptors could develop, survive and function in vivo without the support of healthy retina pigment epithelium (RPE). Visual function was examined through a variety of

Read More
Read More

2020 Life Sciences Sector Report from CLSA Shows Strong Growth in Jobs, Investments and Therapeutic Pipeline in California

SAN FRANCISCO, SACRAMENTO, SAN DIEGO, Calif. & WASHINGTON–(BUSINESS WIRE)–Oct 7, 2020–

California Life Sciences Association (CLSA), the trade association representing California’s life sciences industry, today released the 2020 California Life Sciences Sector Report, which shows that California’s life sciences sector directly employed 323,723 people, generated $191.6 billion in revenue, is projected to attract $6.5 billion in venture capital (VC) and received $4.5 billion in funding from the NIH. Produced with PwC US, the 2020 snapshot highlights the strength of California’s biomedical sector – the largest cluster in the world – as evidenced by significant increases in employment, earnings, graduating science and engineering PhDs, VC investment, and potential new drugs and medical devices in the pipeline.

Key Highlights from 2020 California Life Sciences Sector Report

  • 4.0% increase in total life sciences jobs (up more than 12,000 from prior year), with companies directly employing 323,723 Californians – the most in
Read More
Read More

Novel Therapeutic Technology Developed and Manufactured by ADM Tronics for Origin, Inc., …

Northvale, NJ, Oct. 06, 2020 (GLOBE NEWSWIRE) — via NewMediaWire  — ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has been advised that Origin, Inc. filed an Investigational Device Exemption (“IDE”) application with the FDA to conduct clinical studies to treat patients diagnosed with COVID-19 with its plasma-generated nitric oxide (“NO”) technology.  ADMT has been developing and has manufactured for Origin, Inc. the IonoJet™, which allows for targeted delivery of NO generated by a thermal plasma, produced from room air at the point of therapy.

Michael Preston, Chairman and President of Origin, Inc., stated, “Like other nitric oxide companies, we have recognized the potential ability of NO to stop the replication of corona viruses. We believe there may be limitations with other approaches, and we have worked to address these in a novel system that is designed to allow NO to be administered effectively. ADMT has been key to our development and

Read More
Read More

TriSalus Life Sciences Lays Out Therapeutic Strategy Upon Acquisition of First Therapeutic Candidate

  •  Initiating clinical trials to evaluate investigational toll-like receptor 9 agonist, SD-101, in patients with uveal melanoma liver metastases followed by three additional indications.

  • Aspiring to overcome the challenges of treating patients with solid tumors through our multi-pronged approach to stimulate the immune system and deliver immuno-oncology therapies directly to the site of the disease, with the goal of improving the therapeutic index

  • Working to redefine the treatment of hard-to-treat solid tumors in the liver or pancreas by combining TriSalus’ proprietary FDA cleared intravascular, regional drug delivery technology for liver and pancreatic infusion with investigational SD-101 and standard of care therapy

TriSalus Life Sciences (TriSalus), an emerging immuno-oncology company committed to transforming outcomes for patients with solid tumors, announced today its therapeutic clinical development strategy following the successful acquisition of SD-101, an investigational IND-ready immunotherapy, from Dynavax Technologies on August 3, 2020.

SD-101 is an investigational toll-like receptor 9 (TLR9) agonist

Read More
Read More

Scientists advance the field of precision health with the development of therapeutic artificial cells. — ScienceDaily

New research by an international team of chemists describes a new type of artificial cell that can communicate with other cells within the body — with potential applications in the field of smart pharmaceuticals.

“In the future, artificial cells like this one could be engineered to synthesizes and deliver specific therapeutic molecules tailored to distinct physiological conditions or illnesses — all while inside the body,” explained Sheref Mansy, professor in the University of Alberta’s Department of Chemistry, who co-authored this study in collaboration with researchers at the University of Trento, Italy.

The artificial cells work by detecting changes in their environment within the body. In response, the artificial cell creates and releases a protein signal that influences the behaviour of other cells within the body. “In this way, the changing needs of the host would be rapidly met in a manner that does not flood the entire organism with drug

Read More
Read More